Dermatology

In this interview at AAD 2024, Porter discussed her team’s phase 2 findings on hidradenitis suppurativa the impact of ruxolitinib cream among those with Hurley Stage I and II.

Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.

A secondary analysis from TRuE-AD3 shows ruxolitinib cream significantly benefits pediatric atopic dermatitis patient-reported outcomes.

These phase 3 findings from AAD 2024 suggest patients treated with baricitinib may continue to see scalp, eyelash, and eyebrow hair regrowth with specific dosing regimens.

Thierry Passeron, MD, PhD, discusses the potential benefit of upadacitinib as an oral systemic therapy in patients with nonsegmental vitiligo.

Data presented at AAD 2024 hopes to clarify allergen exposure risks during infancy that may increase risk of allergic contact dermatitis.

The pioneer in neuroimmune research and itch physiology discusses how treatment innovation has evolved dermatology—and what still needs to be changed in practice.

In this interview at AAD 2024, Porter discusses recent data from the SUNSHINE and SUNRISE trials on secukinumab for patients with HS.

Phototherapy is consistently beneficial for patient-reported and clinical outcomes regardless of the location, according to late-breaking data at AAD 2024.

Data from the phase 2 KNOCKOUT study show risankizumab's sustained benefit in reducing memory cells over 52 weeks in psoriasis patients.

These findings from AAD 2024 did not include statistically significant infliximab response predictors, though it had been the largest reported cohort on the subject to date.

A national cohort analysis presented at AAD 2024 showed a significant link between maternal HS exposure and poor health outcomes among children.

In this new analysis presented at AAD 2024, patients with HS saw substantial improvements in their hidradenitis suppurativa-related pain following treatment with bimekizumab.

Lio reviews a field now teeming with FDA-approved options and candidates throughout early-age eczema, psoriasis and more.

New data presented at AAD 2024 highlights challenges in financial status, insurance and comorbidities among black pediatric patients with HS.

With a couple of first-time therapies available for molluscum, Silverberg is interested in learning more about the disease's causes and manifestations.

Advanced practice providers in dermatology discuss exciting developments in the treatment landscape of plaque psoriasis. Listen to their insights into the often-challenging journey patients go on. The arrival of novel oral systemic treatment options offers opportunities to alleviate the burden of this chronic disease.

With drug breakthroughs reaching epidermolysis bullosa, Paller considers what may come next for other rare skin diseases.

A recap of the questions and top comments from our March 04, 2024, pre-AAD LinkedIn Chat highlighting the American Academy of Dermatology's 2024 annual meeting.

Lawrence Eichenfield, MD, reviews prescription and at-home care strategies for pediatric atopic dermatitis, as well as the best measures of disease monitoring.

The AAD's Acne Management Guidelines include updates to the recommendations for treating acne and aims to assist clinicians and patients in making informed decisions on acne management. Test your knowledge with this quiz.

This analysis concluded that the carcinogen known as benzene can be broadly found in concerning levels within benzoyl peroxide (BPO) acne treatment products.

This analysis explored views on safety, general levels of trust, and preferences on examination methods, with the goal being a greater awareness of opinion on AI incorporation.

These data suggest the potential for use of patient-reported outcomes in terms of risk stratification and selection of treatment for patients in both clinical practice and other studies.

In the February edition of Dermatology Month in Review, new acne guidelines released by AAD, an FDA decision on nemolizumab, and an interview on potentially the first oral IL-23 inhibitor for psoriasis were among the major stories.